Discover trends, market shifts, and competitive outlooks for the rotavirus prophylaxis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Projections for the CAGR of the Rotavirus Prophylaxis Market Size From 2025 to 2034?

The market size for rotavirus prophylaxis has rapidly expanded in the previous years. It’s expected to see growth from $9.05 billion in 2024 to $10.03 billion in 2025, with a compound annual growth rate (CAGR) of 10.8%. The historical period’s growth is linked to factors such as vaccine availability and fairness, the emergence of new rotavirus strains, investments in research and development, and public health readiness.

Anticipated to witness robust expansion in the upcoming years, the market size of rotavirus prophylaxis is projected to swell to $14.63 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.9%. This pronounced growth during the forecast span can be assigned to factors such as the prevalence of gastrointestinal diseases, globalization, the implementation of vaccination programs, and an overall confidence in vaccines. Key trends projected to characterize the forecast period encompass next-generation vaccines, combined vaccines, innovations in vaccine delivery, and international collaborations on immunization.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Rotavirus Prophylaxis Market?

The growth of the rotavirus prophylaxis market is likely to be driven by rising vaccine courses, as these specific doses designed to protect individuals from particular diseases are becoming more prevalent. When administered, these vaccine courses trigger an immunological response, offering strong defenses against rotavirus and enhancing the overall efficacy of the vaccine. For example, as per a January 2022 report by UNICEF, a US-based humanitarian and child developmental assistance organization, around 5.71 million doses of the RV1-5 frozen rotavirus vaccine were produced in 2022, and this is projected to go up to 9.31 million by 2028. Also, production of RV5-2 lyophilized rotavirus vaccines reached 5.29 million doses in 2022, and this is expected to rise to 6.13 million by 2028. This growing production of vaccines is therefore expected to spur the growth of the rotavirus prophylaxis market. Investment from various institutions is another significant factor that is likely to fuel the growth of the rotavirus prophylaxis market. These investments, which can take the form of money, effort, or time, are often directed towards financing the necessary requirements, programs, or projects. With the number of rotavirus cases on the rise, these investments from both government and private entities provide financial and technical support at different stages of rotavirus vaccine and medication development. For example, in April 2022, Indiana University, a US-based public research institution, was given a $1.2 million grant from venture capital firm GIVAX Inc for the development of a novel technology for a combined oral rotavirus-norovirus vaccine for infants. This new technology would augment the currently available rotavirus vaccine to also provide protection against norovirus, a highly infectious virus that can lead to severe vomiting and diarrhea in kids. Therefore, the increase in available funding is also likely to give a boost to the rotavirus prophylaxis market.

Which Primary Segments of the Rotavirus Prophylaxis Market Are Driving Growth and Industry Transformations?

The rotavirus prophylaxis market covered in this report is segmented –

1) By Treatment: Rotarix, Rotavac, Rotavin-M1, Oral Rehydration Fluid, Other Treatments

2) By Route of Administration: Oral, Parenteral, Other Route of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Rotarix: Single Dose, Multi-Dose

2) By Rotavac: Liquid Formulation, Freeze-Dried Formulation

3) By Rotavin-M1: Liquid Formulation, Freeze-Dried Formulation

4) By Oral Rehydration Fluid: Electrolyte Solutions, Glucose-Based Solutions

5) By Other Treatments: Supportive Care, Antidiarrheal Medications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13045&type=smp

Which Regions Are Key Players in the Growth of the Rotavirus Prophylaxis Market?

North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Most Significant Market Trends in the Rotavirus Prophylaxis Market?

Big players in the rotavirus prophylaxis market are focusing on the development of vaccines that cater to the needs of customers. Vaccine approval is a stringent procedure that entails multiple phases of development and testing. These approvals are crucial to ensure that vaccines are safe to use and effective at preventing the viral disease, especially in babies and small children. For example, GlaxoSmithKline PLC, a pharmaceutical and biotechnology firm from the UK, reported in November 2022 that the Food and Drug Administration (FDA) had given a green light to a purely liquid, oral-dosing applicator-only presentation of ROTARIX (Rotavirus Vaccine, Live and Oral). This vaccine guards against rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in infants. This unique oral-dosing applicator-only presentation is a liquid formulation that does not need to be reconstituted prior to administration. The lyophilized and liquid versions of ROTARIX are administered orally in two doses, use the same live, human-attenuated rotavirus strain, and are produced using similar equipment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report

What Parameters Are Used to Define the Rotavirus Prophylaxis Market?

Rotavirus prophylaxis refers to the prevention of rotavirus infection through vaccination, which protects infants and young children from a highly infectious illness that causes stomach and bowel inflammation. The purpose is to protect from person from any severity.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13045

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model